Skip to main navigation
ARS Pharma
- ARS Pharma - Investor Relations
  • About
  • In Development
  • Stay Connected
  • Investors & Media
    • Home
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • IR Resources
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us

Press Releases

Mar 28, 2023
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
Mar 23, 2023
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 23, 2023
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
Feb 22, 2023
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
Feb 09, 2023
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

- ARS Pharma - Investor Relations

  • About
  • In Development
  • Stay Connected
  • Investors & Media
    • Home
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • IR Resources
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us

btn >> social icons

twitter linkedin-in

Copyright 2022 © ARS Pharmaceuticals. All rights reserved.